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Abstract
Background: 14-3-3 proteins are a family of highly conserved proteins that are involved in a wide range of cellular
processes. Recent evidence indicates that some of these proteins have oncogenic activity and that they may
promote tumorigenesis. We previously showed that one of the 14-3-3 family members, 14-3-3gamma, is over
expressed in human lung cancers and that it can induce transformation of rodent cells in vitro.
Methods: qRTPCR and Western blot analysis were performed to examine 14-3-3gamma expression in non-small
cell lung cancers (NSCLC). Gene copy number was analyzed by qPCR. P53 mutations were detected by direct
sequencing and also by western blot. CHIP and yeast one hybrid assays were used to detect p53 binding to 14-3-
3gamma promoter.
Results: Quantitative rtPCR results showed that the expression level of 14-3-3gamma was elevated in the majority
of NSCLC that we examined which was also consistent with protein expression. Further analysis of the expression
pattern of 14-3-3gamma in lung tumors showed a correlation with p53 mutations suggesting that p53 might
suppress 14-3-3 gamma expression. Analysis of the gamma promoter sequence revealed the presence of a p53
consensus binding motif and in vitro assays demonstrated that wild-type p53 bound to this motif when activated
by ionizing radiation. Deletion of the p53 binding motif eliminated p53’s ability to suppress 14-3-3gamma
expression.
Conclusion: Increased expression of 14-3-3gamma in lung cancer coincides with loss of functional p53. Hence, we
propose that 14-3-3gamma’s oncogenic activities cooperate with loss of p53 to promote lung tumorigenesis.
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Background
14-3-3 proteins are present in all eukaryotic organisms
that have been examined and are highly conserved
between species. The number of proteins in the 14-3-3
family varies with species. However, in mammals, seven
isoforms have been identified named as b, g, ε, s, ζ, θ
and h, and they function by binding other proteins pre-
dominantly through phosphorylated serine residues
[1,2]. These proteins are highly conserved and are
involved in the regulation of a variety of key physiologi-
cal pathways such as cell cycle progression [3] apoptosis
[4] and mitogenic signaling [5]. Binding target proteins
enable 14-3-3 family members to regulate the activity of
enzymes, control subcellular localization of their targets,
or act as scaffolds that promote protein-protein
interactions.
14-3-3 proteins were identifi e da sa b u n d a n tp r o t e i n s
in the brain and were first described to activate neuro-
transmitter synthesis [6]. Subsequently, they were impli-
cated in a variety of neurological conditions [7]
suggesting that they functioned primarily in the brain.
However, 14-3-3 protein family members are widely
expressed in mammalian tissues and recent evidence
suggests that these proteins may also play a role in the
development of human cancers. Examination of 14-3-3
protein levels in human tumors including lung [8], pros-
tate [9], breast [10], oral [11], ovarian [12] and pancrea-
tic cancers [13,14] indicate that 14-3-3 protein
expression becomes aberrant during tumorigenesis. * Correspondence: jmartinez@azcc.arizona.edu
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bute to tumorigenesis.
Of the 14-3-3 proteins linked to cancer, the best stu-
died is 14-3-3s, which is a transcriptional target of the
p53 tumor suppressor. Activation of p53 by DNA
damage leads to induction of 14-3-3s and G2 arrest [3].
Loss of 14-3-3s also results in defective DNA damage
repair [15] and promotes tumorigenesis in breast epithe-
lia [16]. Moreover, down regulation of 14-3-3s enables
primary human epithelial cells to grow indefinitely [17].
Collectively these findings suggest that 14-3-3s may
function as a tumor suppressor and confirm that 14-3-3
gene expression can be regulated by p53.
T h er o l eo f1 4 - 3 - 3 g isoform in cancer is less well
understood. However, Jin et al. [18] have shown that 14-
3-3g can inhibit transcriptional activity of p53 and we
have previously shown that the 14-3-3g protein is over-
expressed in lung cancers and can promote polyploidy
[19]. In order to gain insight into the role that 14-3-3g
may have in lung tumorigenesis we examined their
expression and the co-occurrence of p53 mutations in
lung tumor specimens. We found evidence suggestive of
a functional interaction between 14-3-3g and p53.
Methods
Frozen human lung tumor specimens and non malig-
nant tissues were obtained from Cooperative Human
Tissue Network, Vanderbilt University Medical Center
(Nashville, TN). 80 samples were selected based on the
tumor type and percentage of tumor cell content (>
70%) and also 21 normal tissues were selected. These
studies were evaluated by the University of Arizona
Human Subjects Protection Program and judged to be
exempt as the specimens are de-identified. The human
lung cancer cells, A549, H358 and H322 cells were
obtained from American Type Culture Collection
(ATCC), USA. The human colorectal cancer cell lines
p53
+/+ and p53
-/- HCT116 were provided by Dr. Bert
Vogelstein (The Johns Hopkins University). Anti-p53
and Anti-14-3-3g antibodies were obtained from Santa
Cruz (Santa Cruz, CA). Antibody to b-actin was pur-
chased from Sigma, St Louis, MO. PCR kits were
obtained from Invitrogen, USA. First strand cDNA
synthesis kit was obtained from Fermentas, USA.
Real-Time PCR quantitation of mRNA expression for 14-3-
3g
The mRNA expression level was determined by quanti-
tative reverse transcription-PCR on total RNA, using the
ABI PRISM 7700 Sequence Detection System. The RNA
was isolated using TRIZOL (Invitrogen, USA) and trea-
ted with DNase to avoid amplification of genomic DNA.
cDNA was synthesized from 500 ng of total RNA and it
was used for PCR. PCR was carried out in 50 μl reaction
mixture containing 25 μl of SYBR Green qPCR Super-
Mix-UDG, 1.5 μlo f1 0μM each forward and reverse
primer, 2 μlo fc D N Aa n dw a t e rt o5 0μl. Thermal
cycling conditions were carried at 50°C for 2 min, 95°C
for 2 min, 40 cycles of 95°C for 30 sec and 58°C for 30
sec using the ABI PRISM 7700 Sequence Detection Sys-
tem. The primers for 14-3-3g and GAPDH transcript
are listed in Table 1. All experiments were repeated
three times. Data are expressed as ΔCt values [ΔCt = Ct
of the target gene (14-3-3g) minus Ct of the GAPDH].
To calculate number of fold changes compared with
normal tissues, 2
-ΔΔCt equation was used; all statistics
were performed with ΔCt values.
Quantitative-PCR for relative gene quantity of 14-3-3g
Normal and tumor specimens were embedded in OCT
and sections were prepared using a MICROM GmbH
cryostat (Waldorf, Germany). The sections were fixed in
75% ethanol and stained in 1.5% eosin for 30 sec. Then
they were washed in 95% ethanol, dehydrated in 100%
high-grade ethanol, incubated with Xylene, air dried,
and subjected to laser capture microdissection (LCM)
using the Veritas Microdissection instrument (Arcturus
Engineering, CA) and CapSure LCM Caps (Arcturus
Engineering, CA). DNA was extracted using the Pico-
pure DNA extraction kit (Arcturus Engineering, CA).
Q-PCR was performed using the ABI PRISM 7700
sequence Detection System (Applied Biosystems, USA)
by TaqMan based technique. The sequences of the
genomic primers and probes used for Q-PCR are listed
in Table 2. The primers were tested to ensure amplifica-
tion of single discrete bands. Relative quantification was
performed using the comparative CT (ΔCT) method. To
normalize the Q-PCR data against aneuploidy that com-
monly occurs in NSCLCs [20], the Ct values of the 14-
3-3g gene are normalized with phosphoinositide-3-
kinase regulatory subunit 1 (PI3KR1) gene, which is
unaltered in NSCLCs [21]. Each real-time qPCR reac-
tion mixture contained 10 μl of DNA sample (obtained
from Picopure DNA extraction kit), 12.5 μl of Platinum
Quantitative PCR SuperMix-UDG (Invitrogen, USA),
0.75 μlo f1 0μM gene-specific forward and reverse pri-
mers, 0.25 μlo f1 0μM fluorescent probe and water to
25 μl. Thermal cycling conditions were carried at 50°C
for 2 min, 95°C for 2 min, 40 cycles of 95°C for 30 sec
and 58°C for 30 sec using the ABI PRISM 7700
Sequence Detection System. Samples were run on a 2%
Table 1 List of primer sequences used for mRNA
expression of 14-3-3g and GAPDH
Forward (5’ >3 ’) Reverse (5’ >3 ’)
14-3-3g CTGAATGAGCCACTGTCGAA GCACGGACCATCTCAATCTT
GAPDH AGGGCCCTGACAACTCTTTT AGGGGTCTACATGGCAACTG
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produced.
RT-PCR and Direct sequencing for p53 mutations
For the mutational analysis of p53 gene exons 5-9, RT-
PCR analysis and direct sequencing were performed.
cDNA from tumor samples was synthesized from 500
ng of total RNA and then PCR was performed using fol-
lowing primers, forward 5’-GCC AAG TCT GTG ACT
TGC ACG-3’ and reverse 5’-AGA GGA GCT GGT
GTT GTT GG-3’. The cycling conditions used for these
PCRs were as follows: 94°C for 5 min, 30 cycles of 94°C
for 30 sec, 55°C for 45 sec and 72°C for 1 min, with a
final extension step of 72°C for 10 min. The PCR pro-
ducts were gel purified using gel purification kit (Qia-
gen, USA). Purified DNA samples were sequenced at
the University of Arizona Genetics Core facility.
Western blot for expression of 14-3-3g, p53 and b-actin
proteins
The protein lysates from either frozen sections or cell
lines were collected using ice-cold RIPA buffer contain-
ing 150 mM NaCl, 50 mM Tris, 1 mM EDTA, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.4 and 2
μl/ml Protease inhibitor cocktail (Sigma, USA). Protein
concentrations were determined using the BioRad pro-
tein assay kit (Biorad, USA) and 50 μg protein was sepa-
r a t e db y1 2 %S D S - P A G Eg e l .T h ep r o t e i n sw e r et h e n
transferred onto a nitrocellulose membrane (Millipore,
USA) and then blocking was carried out by incubating
with 5% nonfat milk in TBST buffer. After blocking, the
membranes were incubated with primary antibodies
raised against human 14-3-3g (Rabbit polyclonal, Santa
Cruz, USA), p53 (DO1, mouse monoclonal, Santa Cruz,
USA) and b-actin for 1 hr. Then the membranes were
washed three times, incubated with secondary-HRP
(Sigma, USA) for 1 hr and then washed with TBST buf-
fer for three times. Blots were developed by Super Signal
West Pico detection system (Pierce, Rockford, IL). The
membranes were stripped and reprobed with b-actin
monoclonal antibody (Sigma, USA) to confirm equal
loading. For frozen tumor specimens, the protein quan-
tification from western blot image was done with the
help of Image J program (NIH, MD) and 2-fold above
the normal is considered as 14-3-3g overexpressing
tumors.
One Hybrid Assays
The Grow’n’Glow GFP One-Hybrid System (MoBiTec,
USA) was used to test for p53 binding to YWHAG pro-
moter sequences. The prey control plasmid pJG4-5-p53,
supplied with the kit, consists of the p53 cDNA fused to
the B42 activation domain; expression of the p53 fusion
protein is under the control of the GAL1 promoter. The
600 and 1200 bp promoter sequences were subcloned
into the GFP reporter vector ("bait” plasmid), pGNG2,
which contains the GFPUV gene driven by the GAL1, 10
minimal promoter. The 600 and 1200 bp fragments
were amplified by PCR from the pGL3 plasmid contain-
ing complete 14-3-3g promoter using the following pri-
mers: 600 bp forward primer, 5’-GAGAGCGGCCGC
GTCGGTCCTCTCCGGCACTT-3’; 1200 bp forward
primer, 5’-GAGAGCGGCCGCATGAACGAGAATA-
TATCAGCGTGACC-3’; reverse primer for both reac-
tions, 5’-GAGAACTAGTCTTCGCGGGGCTGGGTCT-
3’. A NotI recognition sequence is incorporated into the
forward primers; the reverse primer includes a SpeI
recognition sequence. The amplification products and
the pGNG2 plasmid were cut with NotI and SpeI, and
the promoter sequences were ligated into the vector. The
two promoter constructs were verified by sequencing.
The p53 encoding plasmid was co-transformed with
reporter construct into Saccharomyces cerevisiae strain,
W303 and successful transformants selected on -ura -trp
synthetic medium containing dextrose. Individual colo-
nies were inoculated into -ura -trp SC medium with 2%
dextrose and grown to mid-log phase. The cells were
then split in two, washed with sterile water, and resus-
pended in -ura -trp SC medium containing either 2%
sucrose or 2% galactose. After six hours, cell density was
measured spectrophotometrically (OD600)a n d2 0 0μL
aliquots loaded onto a 96-well microplate. The plates
were inspected visually under long wave UV light for
green fluorescence; the fluorescence was quantified using
a plate reader (excitation at 395 nm and emission at 509
nm) (Molecular Devices, USA). The mean values for each
promoter construct and carbon source were normalized
for cell density and expressed as the ratio of fluorescence
in galactose to that in sucrose, the latter set at one fold.
ChIP assays
We collected A549, H358, H322, HCT116p53
+/+ and
HCT116p53
-/- cells for ChIP assay 8h after g-irradiation.
Table 2 List of primer sequences used for amplification of 14-3-3g and PI3KR1 genes by Qpcr
Forward (5’ >3 ’) Reverse (5’ >3 ’) Probe (5’ >3 ’)
14-3-3g CCTCAGCTGCTCGCTCTG CGGAGAAGGAGGAGGACACT 6-FAM-
CGGTCCTCTCCGGCACTTGGGC-TAMRA
PI3KR1 AAGTCTTAAGTTTGGGTTG
AGTCG
TAATGATTGACCAAGCTTTTA
TGC
6-FAM-
TAATGATTGACCAAGCTTTTATGC-TAMRA
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[22]. p53 immunoprecipitation was done with 5 μgo f
antibody against p53 (DO1, Santa Cruz, USA), or with
Mouse IgG (Santa Cruz, USA) as a negative control. We
carried out PCR amplification using primers (forward,
5’-AACCACTGTGGCCAGCCGGTAT-3’; reverse, 5’-
ACAGGAGGCGCGTCCATTGT-3’), designed to give a
product including the p53-binding element. The PCR
protocol was 30 cycles of a 45 sec denaturation step at
94°C, a 1 min annealing step at 58°C and a 1-min exten-
sion step at 72°C. The PCR products were resolved by
1.5% agarose gel electrophoresis.
Plasmid Constructions
To create the pGL3-100, pGL3-586, pGL3-830, pGL3-
840, pGL3-850 and pGL3-1200 14-3-3g promoter plas-
mids, the genomic DNA from human foreskin fibroblast
cells (HFF1 cells, provided by Dr. Rilo, University of Ari-
zona) was PCR amplified with forward primers hanging
KpnI site and reverse primers hanging NheI site, pro-
ducts were digested and gel purified followed by ligation
with KpnI/NheI digested pGL3 linearized vector. For
PGL3-1200 Δ850-840 and PGL3-1200 Δ850-830, 350 bp
fragment upstream of p53 RE (-830 to -850) was ampli-
fied by PCR with forward primer hanging KpnI. 840 and
830 bp downstream from p53RE products were ampli-
fied with reverse primers hanging NheI site. These pro-
ducts were ligated together with KpnI/NheI digested
PGL3 empty vector followed by transformation. All the
promoter reporter constructs were sequenced and con-
firmed at the University of Arizona sequencing facility.
Transfections and Luciferase Assays
All of the transfections were done in triplicate in 24-well
plates. Approximately, 1 × 10
3 cells/well were seeded 24
h before transfection. Plasmids were transfected into cells
using Lipofectamine reagent (Life Technologies, Inc.).
Luciferase assays were performed using the Dual Lucifer-
ase Assay System (Promega, USA) that already contains
an internal control detectable simultaneously with the
luciferase reporter gene. Each experiment was conducted
at least in triplicates. Ad-GFP and Ad-P53-GFP adeno-
viruses are laboratory stocks. Cells were at 60% conflu-
ence when infected with 10MOI. siRNA duplexes
targeting the p53 mRNA was chemically synthesized by
Dharmacon Research. Their target sequences are as fol-
lows: p53, 5’-CAGTCTACCTCCCGCCATA-3’ (p53
siRNA-1) and 5’-GAAGAAACCACTGGATGGA-3’ (p53
s i R N A - 2 ) .T h ec o n t r o ls i R N A si sa sf o l l o w s :5 ’-
GGCTACGTCCAGGAGCGCACC-3’.
Statistical analysis
The statistical analysis was performed by analysis of var-
iance. Only ΔCt values were used for the statistical
analysis of gene amplification and mRNA expression.
The Dunnett’s multiple comparison was used to test the
statistical significance between normal tissues and
tumor tissues. Pearson correlation was used to correlate
fold changes of gene amplification and mRNA followed
by Student’s t-test.
Results
Increased levels of 14-3-3g mRNA in lung tumors
We previously showed using qualitative PCR and immu-
nohistochemistry that transcript levels of six of the seven
different 14-3-3 genes were elevated in human non-small
cell lung cancer (NSCLC) [8]. We showed that one of
these, 14-3-3g,a c t sa sa no n c o g e n ei nf o c u sf o r m a t i o n
assays suggesting that it might play a role in lung tumori-
genesis [23]. In order to gain insight into the mechanism
that resulted in the elevatede x p r e s s i o ni nl u n gt u m o r s ,
we first utilized quantitative rtPCR to quantify the rela-
tive expression levels and to confirm that the expression
of 14-3-3g was transcriptionally elevated. We examined
expression levels of 14-3-3g in 80 frozen samples of non
small cell lung cancer (NSCLC) obtained by surgical
resection through the Cooperative Human Tissue Net-
work. Total RNA was extracted from the frozen tissues;
cDNA was synthesized, and subjected to quantitative RT-
PCR. The levels of 14-3-3g mRNA transcript was signifi-
cantly increased (p < 0.0001), by an average of six fold
when compared to normal tissues (Figure 1A). Western
blotting conducted with a subset of the tumors also con-
firmed that the levels of 14-3-3g was elevated (Figure 1B).
Hence, the elevated levels of mRNA also resulted in ele-
vated protein levels of 14-3-3g.
Overexpression of 14-3-3g does not result from gene
amplification
Since our initial data indicated that 14-3-3g was overex-
pressed in lung cancers, we next sought to determine the
cause of the elevated mRNA levels. One potential expla-
nation is that the 14-3-3g gene may be amplified. Conse-
quently, we determined the relative quantity of 14-3-3g
DNA using quantitative PCR and compared the values
with values obtained from normal tissue. As can be seen
in Figure 1C, the quantity of 14-3-3g gene was altered in
s o m eo ft h et u m o r s ,b u to v e r a l lt h ed a t ad i dn o ts h o wa
significant change when compared with the normal lung
tissue specimens (p < 0.086). Since the gene quantity data
was derived from the same set of tumors as the expres-
sion data, we also tested for a correlation between
increased gene quantity and increased mRNA levels. As
expected, we did not find a correlation between 14-3-3g
gene amplification and overexpression of 14-3-3g mRNA
(p value: 0.336; Pearson correlation coefficient: 0.085).
Therefore, the elevated levels of 14-3-3g mRNA could
not be attributed to an increase in gene copy number.
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mutational status
The observation by Hermeking and coworkers [3]
showing that p53 and 14-3-3 are functionally related
prompted us to determine whether expression of 14-3-
3g was influenced by p53 mutational status. To test
this, we determined the p53 mutational status in our
bank of tumors as described in methods and compared
this with 14-3-3g mRNA expression levels. When we
compared 14-3-3g expression with the occurrence of
Figure 1 Elevated expression of 14-3-3g correlates with mutations in p53. A. mRNA expression in NSCLC tumors. RNA was extracted from
frozen specimens of normal and tumor tissues and the quantity of 14-3-3g determined using quantitative RT-PCR. Fold changes were
determined by 2
-ΔΔCt by comparing Ct values of 14-3-3g with GAPDH. The box plot depicts 2
-ΔΔCt values for 14-3-3g expression. p-values are for
comparison of the levels of 14-3-3g mRNA in tumor specimens with normal tissue, which is calculated using ΔCt values. B. Analysis of 14-3-3g
expression by Western blotting in NSCLC tumors. A Western blot showing expression of 14-3-3g protein in 8 representative NSCLC tumors and
protein loading was confirmed by b-actin. C. Gene copy number. Genomic DNA was extracted from normal and tumor tissues and the relative
quantity of 14-3-3g DNA determined using quantitative PCR from equal quantities of DNA. ΔCt values for 14-3-3g were normalized against PI3KR1
(p85alpha regulatory subunit of PI3K) since the latter was found to be unaltered in NSCLCs. The fold changes were calculated by comparing
normal and tumor tissues using 2
-ΔΔCt. Y-axis shows the fold change comparing normal and tumor tissues. D. 14-3-3g expression and p53
mutations in NSCLC tumors. p53 mutational status was determined in the same lung tumors used in panels A and B using RT-PCR amplification
of p53 mRNA followed by direct sequencing. Tumors were then segregated based on p53 mutation status, (wt-p53) or (mut-p53) and the 14-3-
3g mRNA expression determined as in panel A. p-values were determined by comparing normal tissue, tumors with wt-p53 and tumors with
mut-p53.
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relation between elevated 14-3-3g RNA levels and
mutations in p53 suggesting a functional interaction
between p53 mutations and increased 14-3-3g expres-
sion. The 14-3-3g p r o t e i ne x p r e s s i o ni nl u n gt u m o r s
was also significantly correlated with p53 mutations (p
< 0.0001, Table 3). We also tested for a correlation
between p53 mutations and 14-3-3g gene amplification.
We found no significant difference when we compared
14-3-3g gene amplification with p53 mutational status
( d a t an o ts h o w n ) .T h e r e f o r e ,e l e v a t e d1 4 - 3 - 3 g gene
expression occurs in tumors which have mutations in
p53.
Repression of 14-3-3g mRNA and protein expression by
wt-p53
Our observations in human lung tumors suggested that
wt-p53 might suppress 14-3-3g expression. To explore
this further we began by testing whether activation of
p53 using ionizing radiation had any effect on 14-3-3g.
We exposed three cell lines, A549 (wt-p53), H358 (no
p53 expression) and H322 (mut-p53) to ionizing radia-
tion and then examined the levels of 14-3-3g expression.
A ss h o w ni nF i g u r e2 A ,s t r o n gi n d u c t i o no fp 5 3l e v e l s
was associated with a decrease in the expression of 14-
3-3g in response to g-irradiation. In contrast, no induc-
tion of p53 protein was observed in either H358 or
H322 cells. The same trend was observed in g-irradiated
HCT116 p53
+/+ and HCT116 p53
-/- cells (data not
shown), suggesting that 14-3-3g expression is regulated
by p53. To confirm that the reduced 14-3-3g expression
was due to p53 and not an indirect effect of ionizing
radiation, we examined 14-3-3g mRNA and protein
levels after infection of A549 cells with a p53 expressing
adenovirus. 14-3-3g protein levels were consistently
decreased after transduction with wild-type Adp53 but
not with the GFP-adenovirus control (Figure 2B). Con-
sistent with this, qRT-PCR showed that 14-3-3g mRNA
was decreased almost 30% in cells infected with the wt-
p53-adenovirus when compared with the GFP-adeno-
virus control (Figure 2C). Conversely, suppression of
p53 expression in A549 cells using siRNA led to
increased 14-3-3g protein expression (Figure 2D). These
experiments indicated that p53 could suppress the
expression of 14-3-3g.
Human 14-3-3g gene contains a putative p53 consensus
binding element
Modulation of 14-3-3g expression by p53 could be
either indirect, that is, by inducing another protein
which in turn might regulate 14-3-3g expression, or
direct, by p53 itself binding to the promoter region of
14-3-3g. To determine whether or not p53 could bind
to the promoter region of 14-3-3g we utilized the
GFPUV one-hybrid system, using as “bait” 600 or 1200
bp fragments of the promoter region 5’ to the start
codon and as “prey”, mouse p53. Under long wave UV
light, budding yeast co-transformed with bait and prey
plasmids exhibited strong green fluorescence with 1200
bp promoter fragment. Quantification of GFP emission
revealed that the 1200 bp fragment produced a signifi-
cant GFP signal when compared with sucrose control
which indicated that p53 could bind with the 14-3-3g
promoter (Figure 3A).
p53 protein is a transcription factor that specifically
recognizes and binds to DNA consensus sequences
defined as PuPuPuC(A/T) (T/A)GPyPyPy (N)0-14 PuPu-
PuC(A/T) (T/A)GPyPyPy, in which Pu stands for purine,
Py stands for pyrimidine, and N stands for any nucleo-
tide. Analysis of the human 14-3-3g promoter sequence
using the TF search program revealed the presence of a
putative p53 consensus binding element in the promoter
(Figure 3B). To determine if p53 would indeed bind to
the putative p53 consensus binding elements in human
14-3-3g gene in vivo, ChIP assays were performed in
A549, H322, H358, HCT116 p53
+/+ and HCT116 p53
-/-
cells that were either untreated or exposed to 10 Gy
gamma radiation. We found evidence of p53 binding to
the response element in cells that expressed a wt-p53
a n dt h a tt h i se f f e c tw a se n h a n c e dw i t he x p o s u r et o
ionizing radiation. Little or no binding was observed in
cells that expressed no or mutant p53 (Figures 3C &3D).
Endogenous wt-p53 inhibited the promoter activity of 14-
3-3g
To confirm that p53 could suppress 14-3-3g expression
we cloned 1200 bp of the 14-3-3g promoter and inserted
it into the pGL3 luciferase reporter plasmid and trans-
fected this into A549, H322 or H358 cells which were
either left untreated or exposed to gamma radiation.
Consistent with our CHIP assays, we found that reporter
activity was suppressed by as much as ~50% when the
cells were exposed to radiation, but that reporter activity
was not affected in cells that expressed no or a mutant
p53 (Figures 3E). The repression of 14-3-3g promoter
activity by ectopic expression of wt-p53 suggested that
endogenous p53 could inhibit or modulate 14-3-3g pro-
moter activity. To test whether the p53 repression of
14-3-3g is a physiologically relevant response we exam-
ined the ability of endogenous p53 in A549 cells to
Table 3 Expression of 14-3-3g correlated with mutant p53
No. cancer
tissues
14-3-3g expression
(> 2-fold, %)
P
Total 80 49 (61.2)
P53 wild-type 35 33 (67.3) 0.0001
P53 mutant 45 16 (32.7)
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radiation, a known potent p53 inducer [24]. We rea-
soned that if 14-3-3g is a p53 target gene for repression,
the 14-3-3g promoter activity should be reduced after
p53 induction in cells containing wt-p53 (Figure 3E).
Indeed, we found that 14-3-3g promoter activity was
reduced in irradiated A549 cells, but not in either H358
or H322 cells. To further test this we also examined
reporter activity in HCT116p53
+/+ and HCT116p53
-/-
cells. Consistent with our results in A549 cells we found
that reporter activity was reduced in irradiated
HCT116p53
+/+ but not in HCT116p53
-/- cells or non-
Figure 2 Wt-p53 suppresses expression of 14-3-3g. A. Expression of 14-3-3g and p53 after g-irradiation. Cultures of A549, H358 and H322 cells
were either left untreated (A549, H358, H322) or exposed to 10 Gy of gamma radiation (A549-10 Gy, H358-10 Gy, H322-10 Gy). Total cell extracts
prepared six hours after g-irradiation and proteins fractionated on SDS-PAGE gels. Protein blots were probed for the presence of 14-3-3g and p53
using the appropriate antibodies. The b-actin was used as a loading control. Typical results are shown. B. 14-3-3g protein expression following Ad-
p53 infection. A549 cells were grown and then either left untreated (A549) or infected at a multiplicity of infection (MOI) of 10 with a control
adenovirus expressing GFP (A549-AdGFP) or with an adenovirus expressing a wt-p53-GFP (A549-Adp53). Seventy two hours after infection the
cells were harvested and the presence of 14-3-3g and p53 detected in total cell proteins by immunoblotting using the appropriate antibodies. b-
actin was used as a loading control. C. 14-3-3g mRNA expression following Ad-p53 infection. The relative levels of 14-3-3g mRNA expression in
samples of panel B were quantified using real-time RT-PCR. The bars depict % change compared with control samples from three different
experiments ± SD. Bars showing a significant reduction in message level are marked with an asterisk (p < 0.01 versus Control or Ad-GFP
infected). D. 14-3-3g protein expression following endogenous p53 knockdown by siRNA. A549 cells were cultured and then transfected either with a
control non-targeting siRNA (A549-Mock siRNA) or an anti-p53 siRNA (A549-p53siRNA) as described in Materials and Methods. The cells were
harvested after 48 h, extracts prepared, and protein blots probed for 14-3-3g and p53 using the appropriate antibodies. b-actin was used as a
loading control.
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Page 7 of 11Figure 3 p53 binds 14-3-3g promoter and negatively regulates 14-3-3g expression. A. Yeast one hybrid assays. The 600 and 1200 bp 14-3-
3g promoter sequences were subcloned into the GFP reporter vector as described in materials and methods. The p53 encoding plasmid was
co-transformed with reporter vectors into Saccharomyces cerevisiae strain W303 and successful transformants were used for the GFP fluorescent
assay in the presence of UV. The results were normalized to cells grown in the sucrose medium. Values in y-axis are represented as fold change.
Experiments were repeated three times and p values calculated using student’s t-test (*p < 0.05). B. A schematic diagram of the 1200 bp of the
human 14-3-3g gene promoter is shown with the position and sequence of the putative p53 binding motif identified. The p53 consensus binding
motif is shown for comparison. Asterisks denote identity between the two sequences. This promoter fragment was cloned into PGL3 adjacent to
the luciferase gene (shown at right). C. CHIP assays in lung cancer cell lines. A549, H358 and H322 cells were either left untreated (A549, H358,
H322) or exposed to 10 Gy ionizing radiation (A549-IR, H358-IR, H322-IR). The cells were harvested eight hours after g-irradiation and chromatin
immunoprecipitation performed as described in the methods section. Reactions were performed either with a mouse IgG as a negative control
(A549 -p53ab, H358 -p53ab, H322 -p53ab) or the anti-p53 DO1 antibody. PCR products were separated on agarose gels and visualized by
staining with ethidium bromide and viewing with UV illumination. Three independent experiments were performed. Typical results are shown. D.
CHIP assays in human colon cancer cell lines. HCT116p53
+/+ or HCT116p53
-/- cells were either left untreated or exposed to 10 Gy ionizing
radiation and chromatin immunoprecipitation reactions performed as in panel C using either a mouse IgG as a negative control (-p53ab) or with
the anti-p53 DO1 antibody. PCR products were visualized as in panel C. Reactions using input DNA are shown at the bottom of the panel. Three
independent experiments were performed. A typical result is shown. E. 14-3-3g promoter reporter assays in lung cancer cell lines following g-
irradiation. A549, H322, or H358 cells were transiently transfected either with empty vector (open bars) or with the reporter depicted in panel B
(solid bars). Forty eight hours after transfection the cells were either left untreated (A549, H358, H322) or exposed to ionizing radiation (10 Gy).
The cells were harvested eight hours after gamma-irradiation and luciferase activity measured and normalized relative to renilla luciferase to
control for variations in transfection efficiency. The bars represent the average of three experiments ± SD. An asterisk denotes those values that
are significantly reduced relative to unirradiated controls (*p < 0.01; control vs IR). F. 14-3-3g promoter reporter assays in colon cancer cell lines
following g-irradiation. HCT116p53
+/+ or HCT116p53
-/- cells were treated in the same way as cells in panel E. Luciferase activity was determined in
the non-irradiated and irradiated (IR) cells as described above. The bars depict the average of three independent experiments, ± SD. Open bars
show values for cells transfected with the empty vector. Solid bars show values for cells transfected with the reporter vector shown in panel B.
An asterisk marks those values that were significantly reduced relative to non-irradiated controls (*p < 0.01; control vs IR).
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Page 8 of 11irradiated HCT116p53
+/+ (Figure 3F). These data
strongly supported the notion that 14-3-3g gene expres-
sion is negatively regulated by p53.
The -850 to -830 region is sufficient to mediate p53
repression activity
Finally, we constructed a set of promoter deletion
mutants to test whether p53’s negative regulatory activ-
ities were mediated through the putative consensus
binding site. A 1200 bp stretch of DNA 5’ of the 14-3-
3g gene was cloned and deletions that removed succes-
sively larger regions from the 5’ end of the sequence
were generated and linked to a luciferase reporter. In
addition, we constructed deletions promoter that
removed either part or the entire putative p53 DNA
binding motif. The deletion constructs are diagramed in
Figure 4. To test reporter response to radiation activated
p53, A549 cells were transiently transfected with the
reporter plasmids and then either exposed to radiation
or not and the luciferase activity was measured. As
shown in Figure 4A, the sequences between -586 and
-830 were required for activity of the 14-3-3g promoter
and that the complete p53 consensus binding site was
required for suppression of reporter activity in response
to ionizing radiation.
To further test that p53 could directly repress 14-3-3g,
we infected A549 cells with a wt-p53-GFP adenovirus or
a control GFP-expressing adenovirus and measured luci-
ferase activity (Figure 4B). As can be seen, 14-3-3g pro-
moter activity was down regulated in cells that were
infected with the wt-p53 adenovirus, but not with the
GFP-expressing adenovirus. Moreover, only those repor-
ters that contained the full length p53 binding motif
were negatively regulated by p53. To rule out the possi-
bility that this transcriptional regulation resulted from
the interference of the endogenous p53 by the p53-
expressing adenovirus, we also tested the promoter
activity in human colon cell line HCT116p53
+/+ and
HCT116p53
-/- cells. Consistent with our other experi-
ments, activity of the 14-3-3g promoter with a complete
p53 response element was repressed in HCT116p53
+/+
cells, but not in HCT116p53
-/- cells (Figure 4B). Taken
together our results are consistent with the hypothesis
that the 14-3-3g promoter is negatively regulated by
binding to a p53 DNA binding motif in the promoter
region.
Discussion
The novel finding of this study is that 14-3-3g is nega-
tively regulated by p53 by binding to its promoter. Stu-
dies with human non small cell lung cancers have
shown that expression of 14-3-3g directly correlated
with the p53 status, and elevated protein expression
resulted from an increase in the quantity of mRNA,
suggesting that there is a functional interaction between
elevated 14-3-3g expression and loss of p53. Although
we found some evidence of 14-3-3g gene amplification
in some tumors, there was no significant correlation
with elevated levels of gene expression. Hence, gene
amplification could not account for up regulation of 14-
3-3g expression. Previously, we showed that 14-3-3g
caused polyploidy in lung cancer cell lines suggesting
that elevated levels of expression of this family member
may lead to genomic instability [19]. Therefore, it may
be that increased 14-3-3g expression cooperates with
loss of p53 in the promotion of genomic instability in
lung cancer.
Studies using in vitro experiments showed two lines of
evidence suggesting that p53 repression of human 14-3-
3g is a physiologically relevant response. First, endogen-
ous induction of wt-p53by g-irradiation repressed the
expression of 14-3-3g at the levels of mRNA and pro-
tein. Second, ectopic expression of wt-p53 significantly
suppressed the expression of 14-3-3g. Therefore, overex-
pression of human wt-p53 can exert a strong inhibitory
effect on human 14-3-3g gene expression and tumors
having mut-p53 showed strong expression. Despite the
lack of studies on the regulation of 14-3-3g gene expres-
sion, our findings suggest that p53 could be one of the
regulators, which may, when inactivated, contribute to
the elevated level of 14-3-3g gene expression in tumor
tissues. It is interesting to observe that wt-p53 induced
repression of the human 14-3-3g transcription was
mediated by direct binding to its promoter. The impor-
tant observation is that human 14-3-3g has a p53 bind-
ing site and this site is conserved with the known
reported p53-repressed genes [25]. Here the binding of
p53 to its response element could result in direct
repression of 14-3-3g gene. Interestingly, the other 14-3-
3 isoform, 14-3-3s, which is well studied, is positively
regulated by p53 [3]. Even though 14-3-3g protein
shares more than 80% homology in protein sequence
with 14-3-3s, it is negatively regulated by p53. This
functional difference between the two proteins is still
unclear.
The finding that human 14-3-3g is subject to p53
repression, as reported here, provides the first linkage
between p53, a powerful tumor suppressor, and 14-3-3g,
an oncogene that promotes genomic instability and
tumorigenesis. The fact that the 14-3-3g promoter has a
p53 binding site indicates that 14-3-3g expression is
regulated at the transcriptional level by p53.
Conclusion
In summary, this study has identified 14-3-3g as a
downstream negatively regulated p53 target protein and
that loss of p53 function leads to over expression of 14-
3-3g in lung cancer. Our studies may provide the basis
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Page 9 of 11Figure 4 Deletion of the p53 binding motif in the 14-3-3g promoter eliminates suppression by p53. A series of deletion mutants were
constructed that successively deleted segments from the 5’ end of the 14-3-3g promoter. These are illustrated diagrammatically linked to a
luciferase gene and are shown on the left side of panels A and B. The p53 binding motif is represented as a small striped box. Small boxes
outlined with stippled lines show the position of p53 consensus sequences that were deleted. The numerical designation shown within the
luciferase box indicates the length of the 14-3-3g promoter sequence attached to the luciferase gene. A. Endogenous p53 repress wild-type 14-3-3g
promoter activity after g-irradiation. Luciferase reporter vectors each containing either no 14-3-3g promoter sequences (PGL3-LUC), 14-3-3g
promoter sequences of various lengths (PGL3-100 bp-LUC, PGL3-586 bp-LUC, PGL3-830 bp-LUC, PGL3-1200 bp-LUC), or 14-3-3g promoter
sequences that lacked either all or part of the p53 consensus binding sequence (PGL3-840 bp-LUC, PGL3-850 bp-LUC, PGL3-1200Δ850-840 or
PGL3-1200Δ850-830) were transiently transfected into A549 cells together with a renilla luciferase vector. Forty-eight hours after transfection the
cells were either left untreated (open bars) or irradiated with 10 GY ionizing radiation (solid bars). The cells were harvested 12 hours later,
extracts prepared and luciferase activity quantified. The bars in the graph at the right of panel A represent the mean ± SD of three independent
experiments. Values that were determined to be significantly reduced relative to the matched control are marked with an asterisk (p < 0.01;
control vs IR). B. 14-3-3g wild-type and mutant promoter reporter assays in A549 and HCT116 cells. The 14-3-3g promoter deletion reporter vectors
described in panel A were transfected into A549 cells that are infected with either GFP-expressing adenovirus (open bars) or with an adenovirus
expressing a wt-p53 (solid bars). Forty-eight hours later the cells were harvested and luciferase activity quantified and normalized to renilla
luciferase activity. Bars in the graph in the middle of panel B represent the mean of three independent experiments ± SD. Values that were
found to be significantly reduced relative to the matched control are marked with an asterisk (p < 0.01; Ad-GFP vs Ad-p53). In a similar
experiment, HCT116p53
+/+ (open bars) and HCT116p53
-/- (closed bars) with the same vectors described above and irradiated with 10 Gy ionizing
radiation. Luciferase activity was determined and normalized to renilla luciferase and the values graphed. Results shown represent the mean of
three independent experiments ± SD. Values determined to be significantly reduced relative to their matched controls are marked with an
asterisk (p < 0.01; HCT116 p53
+/+ vs HCT116 p53
-/-).
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Page 10 of 11for further understanding of the role of 14-3-3g in lung
tumorigenesis and may open up potential targets for
therapeutic approaches.
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